AMRN

Amarin is a single-product story in structural decline. VASCEPA (icosapent ethyl) faces generic competition that keeps eroding both price and share: the MD&A states U.S. product revenue fell 8% on a lower net selling price, branded prescriptions dropped 10%, and Amarin's share of the icosapent ethyl market slid from ~53% to ~47% in 2025 — even as the overall market grew 2%. That is a franchise losing ground on all fronts. Revenue has fallen every year for four years ($583M→$369M→$307M→$229M→$214M), and with R&D only $19.8M there is no visible pipeline to replace the runoff. This is the core reason it is not a buy.

The offsetting case is a real one. Management is executing a credible harvest: SG&A was cut 24% (selling expense down 49%), COGS fell 37%, product gross margin ex-charges held near 49%, and the net loss narrowed from -$82.2M to -$38.8M while operating cash flow turned positive at $6.73M. Licensing/royalty revenue rose 29% to $30.9M, helped by a $25M Recordati upfront and modest ex-U.S. growth (Europe $18.4M vs $13.7M) — a slow pivot away from total U.S. dependence. The balance sheet is genuinely strong: $135M cash, no current debt, liabilities/equity just 0.46x, and current assets ($650M) more than triple current liabilities.